What Does a Psychedelic Therapy Episode Actually Cost?

When we ask what a psychedelic therapy episode costs, the first number that comes to mind is usually the price of the drug. That makes sense. It is a visible product with a price that can often be named. But buying the medicine is only one part of delivering the care around it.

Someone has to decide whether the treatment is suitable, prepare the patient, provide and monitor the session, and follow up afterwards. In many psychedelic therapy protocols, those parts are described simply as preparation, the dosing session, and integration. Adding the medicine gives us four useful places to start.

More costs sit around these four parts: rooms, equipment, training, scheduling, insurance, and the time lost when a long appointment is cancelled. We will add those as we go. For now, the basic variables are easy to picture: how many hours of care are needed, how many people provide it, what those hours cost, how long a room is occupied, and what the medicine costs.

The interactive tally beside this article uses a psilocybin treatment for treatment-resistant depression as an illustrative reference case. It starts with the medicine and lead therapist. As you read, it adds preparation, an assisting therapist, the dosing room, integration, and costs shared across the service. Click the downward arrow beside any line item to change its inputs, or use the Low, Reference, and High settings to compare three sets of assumptions. On a smaller screen, the tally sits above the article.

A treatment episode can mean very different things. At its simplest, it might mean paying for one visit at a private ketamine clinic: arrive, receive an infusion, recover, and go home. In that case, the episode is close to a single appointment.

The psychedelic therapy model usually discussed for psilocybin or MDMA is broader. It includes work before the dosing day, several hours of supported treatment, and one or more meetings afterwards. The episode may therefore run across days or weeks, even if the medicine is given only once.

For this article, the main boundary is the planned first course: screening, preparation, administration, and short follow-up or integration. A wider view could also count maintenance, reauthorisation, missed appointments, relapse, and retreatment. Those later costs matter, but they need a longer time horizon and better real-world evidence.

To make the tally concrete, it follows one COMP360-style administration episode: preparation, one 25 mg dosing day, and short integration. It does not automatically add a second dose, retreatment, or trial-only research visits. Those would extend the pathway and add another set of costs.

The medicine is the easiest line to recognise, but even here we need to be precise. The relevant figure is usually the provider or pharmacy's acquisition cost, not the charge shown to a patient and not the payment eventually allowed by an insurer.

For the tally, we use COMP360 as the example of a future branded psilocybin medicine. Compass is submitting it for FDA review and anticipates a possible US launch in the first half of 2027, subject to approval and rescheduling. As of 13 July 2026, the company has not published a US list or acquisition price.

The $3,000, $7,500, and $15,000 medicine settings are therefore sensitivity cases, not a forecast of what Compass will charge. The $7,500 reference case makes a potentially substantial branded-drug price visible in the total; it should be replaced when a price is disclosed. These settings describe one possible branded-medicine pathway, not the full range of ways psilocybin could be supplied.

MDMA shows how high a developer-led assumption can go. A 2024 health-economic model funded by Lykos Therapeutics, now Resilient Pharmaceuticals, assumed a medicine price of $12,000 for each of three MDMA administrations: $36,000 for the drug across the course. This was a modelling input, not a published list price. Marseille and Mitchell later criticised that assumption and explored about $10,500 for all three doses as a more accessible alternative.

A regulated service model can put the drug line much lower. Oregon's June 2026 revenue forecast reports an average psilocybin-product price of about $40. Most of the overall session price goes to the service centre and facilitator, not the product. Oregon's product is not an FDA-approved branded medicine, so it is not a like-for-like comparison with COMP360. It does show that a costly care episode does not necessarily require a costly drug. The calculator's $3,000 low scenario is therefore not a market floor; readers can enter a lower figure themselves.

Australia offers another useful warning about labels. Approved psychiatrists can arrange regulated supplies of unapproved MDMA or psilocybin through sponsors, importers, and pharmacies. Yet we could not find a defensible public drug-only acquisition price. One Australian clinic reported full-course prices of about AUD $20,000 for psilocybin therapy and AUD $30,000 for MDMA therapy in May 2026. Those are complete programme prices, not medicine prices, and should not be entered as the drug line in the tally.

Current real-world products show why the line matters. A Veterans Affairs service reported medicine acquisition of $0.40 per intramuscular ketamine treatment and $690 per intranasal esketamine treatment, while its direct staff cost was $68.67 in both groups. Those figures are useful comparators, not estimates of a future COMP360 price.

Branded-medicine sources: Compass's July 2026 SEC filing, the Lykos-funded MDMA cost-effectiveness model, the MAPS update identifying Resilient as the company's current name, and Marseille and Mitchell's critique.

Regulated-service sources: Oregon's June 2026 economic and revenue forecast, Australia's TGA access guidance, the DVA funding guidance, and the Australian clinic report. The ketamine comparison is the 2026 VA study of intranasal esketamine and IM ketamine. Read the study.

The episode starts before anyone books a dosing room. A service has to confirm the diagnosis, previous treatment, current medicines, medical risks, and practical ability to complete the pathway. Depending on the treatment and setting, that can involve a psychiatric assessment, physical checks, laboratory tests, consent, prior authorisation, and coordination with the patient's usual clinicians.

Screening also includes people who do not proceed. Some will be ineligible. Others will decide not to continue, be unable to arrange transport, or lose coverage before administration. A provider still used intake and clinical time. If payment only begins on the dosing day, the service carries that cost.

An economic analysis of Phase III MDMA-assisted therapy assigned 5.6% of its $11,537 intervention microcost to screening and intake after adjusting for a 57.3% screen-out rate. That percentage applies to one investigational protocol and should not be transferred to psilocybin, ketamine, or routine care. The narrower lesson is that failed screens consume resources even when no treatment follows.

Preparation is part of the clinical pathway, but payment for it is often unclear. It can cover expectations, safety planning, the therapeutic relationship, transport, and what to do if the experience becomes difficult. Trials specify this work because it is part of the protocol. A routine service must also decide who provides it, how long it takes, and whether the payer covers it.

Source: Marseille and colleagues' MDMA-assisted therapy economic analysis.

The dosing day is often the most visible part of the episode. It is also where several costs arrive together. The medicine is given inside a staffed room, with monitoring, equipment, recovery time, and a plan for getting the patient home safely.

Time is the first major variable. One private IV ketamine clinic describes a 45-minute infusion within a visit of about 90 minutes. Esketamine requires at least two hours of observation after administration. Psilocybin and MDMA research sessions can occupy six to eight hours. A longer session does not only add clinician hours; it also blocks the room for other care.

Staffing is the second variable. A pathway may use one clinician, a therapist pair, nursing support, a prescriber who remains available, or some combination of these. Setup, handovers, documentation, recovery, and room turnover can extend beyond the time when the medicine is having its main effect.

Sources: the named IV ketamine clinic example, the FDA Spravato label, a COMP360 phase II report, and the MDMA-assisted therapy protocol analysis.

Care often continues after monitoring ends. Services may provide a safety call, integration, psychotherapy, symptom measurement, medication review, or coordination with a referring clinician. Someone also has to complete documentation, submit claims, respond to denials, and schedule the next step.

Integration can account for a sizeable share of delivery cost. In the Phase III MDMA-assisted therapy microcost, integration accounted for 27.4% of the total intervention cost. That figure does not establish what integration should cost in another pathway or whether other treatments need the same model. It does show that integration was a substantial component of this therapy-intensive protocol.

One provider's posted cash packages offer a second comparison. On 13 July 2026, it advertised $3,475 for six IV infusions and $4,466 for six infusions plus six integration sessions. The $991 difference is a posted price, not the provider's delivery cost or evidence that integration improves outcomes. The comparison isolates what this provider charges for adding six integration sessions.

Sources: the MDMA-assisted therapy analysis and Stella's advertised prices.

Some costs cannot be assigned neatly to one patient or visit. A clinic pays rent even when a room is empty. Staff training may happen months before the first treatment. Insurance, governance, controlled-drug procedures, software, and management support the whole service. These costs have to be recovered across the patients a site can actually treat.

Volume determines how widely fixed costs can be spread. A service that trains a team and treats hundreds of patients can spread its start-up costs further than a low-volume site. The same is true of a purpose-built room. Dividing an annual lease by assumed session volume gives an estimated room cost, not an observed one.

Regulatory requirements show the time commitment more clearly than they show a universal per-patient cost. Oregon's regulated psilocybin model requires 128 hours of core training and a 40-hour practicum. From 2026, facilitator renewals also require at least four hours of continuing education each year. Those requirements belong to Oregon's service model, not to clinical psilocybin delivery everywhere. They show why “training” needs more than one row in a cost spreadsheet.

Sources: Oregon core-training requirements, practicum requirements, and current continuing-education requirements.

A single low-to-high range would combine figures that answer different questions. A VA direct cost, an Australian trial microcost, a Colorado Medicaid fee-schedule amount, and a private clinic package do not share a perspective or denominator.

The table below keeps those numbers separate. Each one can help with a particular question. None is a universal estimate of what psilocybin, MDMA, ketamine, or esketamine therapy “really costs”.

Ketamine and esketamine appear several times because they offer some of the clearest current real-world examples of medicine, staff, monitoring, package-price, and payment components. They ground the discussion; they do not define the resource use of every psychedelic therapy.

The calculator is a way to see how the line items add up. Its low, reference, and high settings are sensitivity cases for one COMP360-style administration episode in the US. They are not observed percentiles and not estimates of what every treatment should cost. Every input can be changed or removed.

Compass has not disclosed a future US price for COMP360. The medicine settings of $3,000, $7,500, and $15,000 are deliberately broad, editable assumptions. They should not be read as company guidance, analyst consensus, or a market range.

The care pathway is more firmly grounded. In Compass's published phase II trial, participants met a therapist at least three times before dosing. The administration lasted six to eight hours with a lead and assisting therapist present, and was followed by two integration meetings. The reference tally uses three preparation hours, eight hours for each of the two session staff, and three integration staff-hours. Session length and staffing come from the trial; meeting length remains an assumption.

The hourly staff settings use current US wage data as a starting point. In May 2025, median hourly wages were $28.53 for mental- health counsellors and $48.36 for clinical and counselling psychologists. Benefits accounted for 29.6% of private health- care and social-assistance compensation in March 2026. The calculator's higher clinical rate allows for more senior or specialist staffing, but it remains an assumption rather than a national tariff.

Room cost, training allocated to one episode, and the unused- capacity buffer are deliberately not presented as sourced US averages. Public evidence does not support one national figure. They are visible assumptions so a service can replace them with its own rent, expected volume, cancellation rate, and training plan.

Reference points: the VA cost comparison, the COMP360 phase II report, a Compass protocol description, the May 2025 BLS wage estimates, and the March 2026 BLS compensation report.

Public sources describe protocols better than they describe routine operations. We often know the intended session length, dose, and staffing model. We know less about the minutes each staff role actually spends, how long the room remains blocked, how many referrals fail screening, how often patients cancel, what payers allow after negotiation, and how much work goes into denials and collections.

Evidence on overhead is especially sparse. A paper may add a percentage for scheduling and documentation, but that does not establish a general psychedelic-clinic overhead rate. A provider may post a cash price, but that does not reveal rent, wages, utilisation, insurance, or margin. Where evidence is missing, adding a generic percentage creates false precision.

Real services could fill these gaps by recording staff minutes by role, room occupancy, medicine and pharmacy costs, screen-outs, no-shows, training time, administrative work, payment received, and care after the initial course. Until then, ranges should remain attached to named pathways and named perspectives.